StockNews.com Initiates Coverage on BIOLASE - Defense World

BIOLDelisted Stock  USD 0.05  0.02  27.46%   
About 61% of BIOLASE's investor base is looking to short. The analysis of current outlook of investing in BIOLASE suggests that many traders are alarmed regarding BIOLASE's prospects. BIOLASE's investing sentiment shows overall attitude of investors towards BIOLASE.
  
StockNews.com Initiates Coverage on BIOLASE Defense World

Read at news.google.com
Google News at Macroaxis
  

BIOLASE Fundamental Analysis

We analyze BIOLASE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIOLASE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIOLASE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

BIOLASE is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

BIOLASE Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BIOLASE stock to make a market-neutral strategy. Peer analysis of BIOLASE could also be used in its relative valuation, which is a method of valuing BIOLASE by comparing valuation metrics with similar companies.

Peers

BIOLASE Related Equities

PACBPacific Biosciences   8.52   
0%
100.0%
TIVCTivic Health   4.00   
0%
46.0%
NNOXNano X   2.87   
0%
33.0%
HSCSHeart Test   1.72   
0%
20.0%
BJDXBluejay Diagnostics   0.57   
0%
6.0%
VVOSVivos Therapeutics   0.29   
0%
3.0%
BVSBioventus   0.16   
0%
1.0%
DXCMDexCom   0.14   
1.0%
0%
NAOVNanoVibronix   1.37   
16.0%
0%
TNDMTandem Diabetes   1.89   
22.0%
0%
BBLGBone Biologics   3.17   
37.0%
0%
NUWENuwellis   3.62   
42.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Consideration for investing in BIOLASE Stock

If you are still planning to invest in BIOLASE check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BIOLASE's history and understand the potential risks before investing.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments